Keeping Track: UCB’s Very Good Day, Pfizer’s Great Year
Pfizer adds Velsipity and Penbraya to its US FDA novel approval haul and UCB’s Bimzelx finally achieves FDA clearance, along with Zilbrysq.
You may also be interested in...
The unusual move may be temporary as CDC plans to spend the next year working to revise the adolescent schedule for meningococcal vaccines. Pfizer indicated the decision might lead to a price shift for the recently approved Penbraya.
Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.
Branded as Velsipity, the S1P modulator will compete directly against classmate Zeposia in UC and faces a crowded field of anti-TNFs and other types of therapy. Pfizer paid $6.7bn for Arena in 2021.